scholarly journals Downregulation of microRNA-206 suppresses clear cell renal carcinoma proliferation and invasion by targeting vascular endothelial growth factor A

2015 ◽  
Vol 35 (3) ◽  
pp. 1778-1786 ◽  
Author(s):  
YI CAI ◽  
HANZHONG LI ◽  
YUSHI ZHANG
Keyword(s):  
Vascular Endothelial Growth Factor ◽  
Growth Factor ◽  
Renal Carcinoma ◽  
Clear Cell ◽  
Vascular Endothelial ◽  
Clear Cell Renal Carcinoma ◽  
Cell Renal Carcinoma ◽  
Endothelial Growth Factor ◽  
Proliferation And Invasion

scholarly journals Prognostic Value of Vascular Endothelial Growth Factor A in the Prediction of the Tumor Aggressiveness in Clear Cell Renal Cell Carcinoma

2017 ◽  
Vol 5 (2) ◽  
pp. 167-172 ◽  
Author(s):  
Fahredin Veselaj ◽  
Suzana Manxhuka-Kerliu ◽  
Arber Neziri ◽  
Labinot Shahini ◽  
Shefki Xharra ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Vascular Endothelial Growth Factor ◽  
Growth Factor ◽  
Renal Cell ◽  
Prognostic Value ◽  
Clear Cell ◽  
Vascular Endothelial ◽  
Cell Renal Cell Carcinoma ◽  
Free Survival ◽  
Endothelial Growth Factor

BACKGROUND: Clear cell renal cell carcinoma (CCRCC) is the most predominant renal tumour with unpredictable tumour behaviour. The aim of the study is to investigate the prognostic value of vascular endothelial growth factor A (VEGF-A) expression in CCRCC and to correlate it with other histological parameters as well as with patient's survival.MATERIAL AND METHODS: Tumour blocks were taken from 40 patients with histopathology diagnosis of CCRCC and tissue block from 20 normal kidneys as a control group were examined using the immuno-histochemical staining for VEGF-A.RESULTS: The VEGF A expression in CCRCC was significantly higher than in the normal kidney tissues (U’ = 720, P < 0.0001). VEGF A expression values in CCRCC were positively correlated with Disease Free Survival (r = 0.335, P = 0.034) and the tumor necrosis degree (r = 0.181, P = 0.262). VEGF-A expression values in CCRCC did not correlate with CD 31 expression (r = -0.09, P = 0.549), and Progression Free Survival (r = -0.07, P = 0.838). VEGF A expression values in CCRCC were negatively correlated with the tumor nuclear grade (r = -0.161, P = 0.318); the pathological tumor stage (r = -0.371, P = 0.018); the tumor size (r = -0.361, P = 0.022); the degree of tumor hemorrhage (r = -0.235, P = 0.143); and Cancer Specific Survival   (r = -0.207, P = 0.713).CONCLUSIONS: VEGF-A expression can be used to stratify advanced and metastatic CCRCC patients into low-benefit and high-benefit groups. Based on this study outcome it would be useful to perform IHC staining for VEGF-A expression in all patients with advanced and metastatic CCRCC.

Effect of Vascular Endothelial Growth Factor and Its Receptor Inhibitor on Proliferation and Invasion in Bladder Cancer

2009 ◽  
Vol 83 (1) ◽  
pp. 98-106 ◽  
Author(s):  
Ryoichi Nakanishi ◽  
Natsuo Oka ◽  
Hiroyoshi Nakatsuji ◽  
Takahiro Koizumi ◽  
Manabu Sakaki ◽  
...  
Keyword(s):  
Vascular Endothelial Growth Factor ◽  
Bladder Cancer ◽  
Growth Factor ◽  
Vascular Endothelial ◽  
Endothelial Growth Factor ◽  
Proliferation And Invasion ◽  
Receptor Inhibitor

Treatment of Metastatic Renal Cell Carcinoma With a Combination of Bevacizumab and Erlotinib

2005 ◽  
Vol 23 (31) ◽  
pp. 7889-7896 ◽  
Author(s):  
John D. Hainsworth ◽  
Jeffrey A. Sosman ◽  
David R. Spigel ◽  
Donna L. Edwards ◽  
Cara Baughman ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Growth Factor ◽  
Cell Carcinoma ◽  
Skin Rash ◽  
Renal Cell ◽  
Renal Carcinoma ◽  
Clear Cell ◽  
Targeted Agents ◽  
Clear Cell Renal Carcinoma ◽  
Cell Renal Carcinoma

Purpose To evaluate the efficacy and toxicity of combined treatment with two targeted agents, an antibody against vascular endothelial growth factor (bevacizumab) and an epidermal growth factor receptor tyrosine kinase inhibitor (erlotinib), in the treatment of patients with metastatic clear-cell renal carcinoma. Patients and Methods Sixty-three patients with metastatic clear-cell renal carcinoma were treated with bevacizumab 10 mg/kg intravenously every 2 weeks and erlotinib 150 mg orally daily. Patients were reevaluated after 8 weeks of treatment; patients who responded continued treatment until they experienced tumor progression. Results Fifteen (25%) of 59 assessable patients (95% CI, 16% to 37%) had objective responses to treatment, and an additional 36 patients (61%) had stable disease after 8 weeks of treatment. Only eight patients' (14%) disease had progressed at this time point. The median and 1-year progression-free survivals were 11 months and 43%, respectively. After a median follow-up of 15 months, median survival has not been reached; survival at 18 months was 60%. Treatment was generally well tolerated; only two patients discontinued treatment because of toxicity (skin rash). Grade 1/2 skin rash and diarrhea were the most frequent treatment-related toxicities. Conclusion The combination of bevacizumab and erlotinib is an effective and well-tolerated treatment for patients with advanced renal cell carcinoma. The efficacy of these two drugs in combination suggests that targeting of separate pathways critical to tumor growth and dissemination may achieve results superior to either drug as a single agent. Additional development of this and other combinations of targeted agents is warranted.

Sign in / Sign up

Export Citation Format

Share Document